59557-90-3

Basic information

• Product Name: 4-BROMO-3,5-DIMETHYLANILINE
• Synonyms: 4-Bromo-3,5-dimethylbenzenamine;4-Bromo-3,5-xylidine;5-Amino-2-bromo-m-xylene;BenzenaMine, 4-broMo-3,5-diMethyl-
• CAS NO: 59557-90-3
• Molecular Formula: C₈H₁₀BrN
• Molecular Weight: 200.08
• Mol File: 59557-90-3.mol
• Article Data: 16

Chemical Properties

• Melting Point: 73-74°C
• Boiling Point: 260.992 °C at 760 mmHg
• Flash Point: 111.644 °C
• Appearance: /
• Density: 1.425 g/cm³
• Storage Temp.: Room temperature.
• PKA: 4.14±0.10(Predicted)
• CAS DataBase Reference: 4-BROMO-3,5-DIMETHYLANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-3,5-DIMETHYLANILINE(59557-90-3)
• EPA Substance Registry System: 4-BROMO-3,5-DIMETHYLANILINE(59557-90-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 59557-90-3(Hazardous Substances Data)

Usage

General Description

4-Bromo-3,5-dimethylaniline is a chemical compound with the molecular formula C8H10BrN. It is a substituted derivative of aniline, with a bromine atom and two methyl groups attached to the aromatic ring. 4-BROMO-3,5-DIMETHYLANILINE is commonly used in organic synthesis as a building block for the preparation of various pharmaceuticals, agrochemicals, and dyes. It is also used as an intermediate in the production of pesticides, pharmaceuticals, and other organic compounds. 4-Bromo-3,5-dimethylaniline is a light-sensitive, yellowish to off-white crystalline solid with a strong odor, and it should be handled with caution due to its potential health hazards and environmental impact.

Upstream product

• 53906-84-6 2-bromo-1,3-dimethyl-5-nitrobenzene 
• 108-69-0 3,5-dimethylaminoaniline 
• 64835-48-9 N-(4-bromo-3,5-dimethylphenyl)acetamide 
• 2423-71-4 2,6-dimethyl-4-nitro phenol 
• 16947-63-0 2,6-dimethyl-4-nitroaniline 
• 195383-84-7 acetic acid-(3-bromo-2,4-dimethyl-anilide) 
• 195389-20-9 3-bromo-2,4-dimethyl-6-nitro-aniline 
• 99-12-7 5-nitro-m-xylene 
• 576-22-7 2-Bromo-m-xylene 

Downstream Products

• 82051-86-3 N,N-di-benzyl-4-bromo-3,5-di-methylaniline 
• 100189-84-2 2,5-dibromo-1,3-dimethylbenzene 
• 689260-53-5 2-bromo-5-iodo-1,3-dimethylbenzene 
• 689260-65-9 2,5-dibromo-1,3-bis(bromomethyl)benzene 
• 740815-82-1 2,5-dibromo-1,3-bis(cyanomethyl)benzene 
• 312304-54-4 1-bromo-4-iodo-2,6-bis[(dimethylamino)methyl]benzene 
• 53906-84-6 2-bromo-1,3-dimethyl-5-nitrobenzene 
• 361436-27-3 tert-butyl (4-bromo-3,5-dimethylphenyl)carbamate 
• 910654-18-1 C₂₁H₂₆BrNO 
• 1058661-88-3 (E)-tert-butyl 3-(4-amino-3,5-dimethylphenyl)acrylate 
• 1021165-59-2 N-(4-formyl-3,5-dimethyl-phenyl)-acetamide 
• 64835-48-9 N-(4-bromo-3,5-dimethylphenyl)acetamide 
• 1021162-15-1 2-(4-acetylamino-2,6-dimethyl-phenyl)-3H-benzoimidazole-5-carboxylic acid (3,4-dimethyl-phenyl)-amide 
• 1332883-54-1 ((4-bromo-3,5-dimethylphenyl)ethynyl)triisopropylsilane 

Relevant articles and documents

Synthesis and anti-diabetic activity of novel biphenylsulfonamides as glucagon receptor antagonists

Type 2 diabetes is characterized by chronic hyperglycemia. Insulin, a hormone secreted from pancreatic β-cells, decreases blood glucose levels, and glucagon, a hormone secreted from pancreatic α-cells, increases blood glucose levels by counterregulation of insulin through stimulation of hepatic glucose production. In diabetic patients, dysregulation of glucagon secretion contributes to hyperglycemia. Thus, inhibition of the glucagon receptor is one strategy for the treatment of hyperglycemia in type 2 diabetes. In this paper, we report a series of biphenylsulfonamide derivatives that were designed, synthesized, and then evaluated by cAMP and hepatic glucose production assays as glucagon receptor antagonists. Of these, compound 7aB-3 decreased glucagon-induced cAMP production and glucagon-induced glucose production in the in vitro assays. Glucagon challenge tests and glucose tolerance tests showed that compound 7aB-3 significantly inhibited glucagon-induced glucose increases and improved glucose tolerance. These results suggest that compound 7aB-3 has therapeutic potential for the treatment of type 2 diabetes.

BIARYL UREA DERIVATIVE OR SALT THEREOF, AND MANUFACTURING AND APPLICATION OF SAME

The present invention discloses a biaryl urea RORγt inhibitor, and specifically relates to a biaryl urea derivative, as represented by formula I, with an RORγt inhibiting activity, and a preparation process thereof, and a pharmaceutical composition comprising the compound. Further disclosed is use of the compound for treating an RORγt-related disease.

Orthogonal switching in four-state azobenzene mixed-dimers

Azobenzene multi-state switches whose isomerization can be orthogonally induced with photons and electrons are presented. Exposure to green, blue, or ultraviolet light allows toggling between three isomers, while the fourth one is formed selectively via electrocatalytic isomerization.